- Home
- FULT vs VKTX Comparison
FULT vs VKTX Comparison
Compare FULT & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FULT | VKTX |
|---|---|---|
| Founded | 1882 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | FULT | VKTX |
|---|---|---|
| Price | $19.63 | $35.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $21.40 | ★ $88.00 |
| AVG Volume (30 Days) | 1.7M | ★ 2.5M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.75 | N/A |
| Revenue Next Year | $5.56 | N/A |
| P/E Ratio | $10.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.33 | $18.92 |
| 52 Week High | $22.99 | $43.15 |
Technical Indicators
Market Signals| Indicator | FULT | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.68 | 61.29 |
| Support Level | $19.15 | $33.65 |
| Resistance Level | $19.97 | $39.13 |
| Average True Range (ATR) | 0.59 | 1.64 |
| MACD | -0.21 | 0.40 |
| Stochastic Oscillator | 9.57 | 76.34 |
Price Performance
Historical ComparisonAbout FULT Fulton Financial Corporation
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.